Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

From Availability To Awareness: 2007 Brings Wide Range Of Goals For CHPA

This article was originally published in The Tan Sheet

Executive Summary

The Consumer Healthcare Products Association looks to focus its efforts in 2007 on issues such as Rx-to-OTC switches, rising health care costs, consumer education and prevention of OTC abuse. CHPA President Linda Suydam recently spoke with "The Tan Sheet" about the association's accomplishments during 2006 and goals for the coming year

You may also be interested in...



Citizen Petition On Phenylephrine Requests Pulling OTC Status For Children

A citizen petition asks FDA to withdraw OTC approval for phenylephrine use by children under 12 years old and to raise the maximum dose to 25 mg, but also recommends more research to determine the most effective dosage level

Dextromethorphan Bulk-Sale Limit Clears House, But Stalls In Senate

House leadership made a lame duck priority of legislation to restrict sales and distribution of bulk forms of dextromethorphan (DXM), but HR 5280 did not get the same treatment in the Senate

Waxman Renews Push For FDA Examination Of Phenylephrine Efficacy

Schering-Plough's decision to sell Claritin-D behind the counter rather than reformulate with the nasal decongestant phenylephrine has prompted Rep. Henry Waxman (D-Calif.) to renew his request for an FDA review of the ingredient's efficacy

Related Content

Topics

UsernamePublicRestriction

Register

PS100227

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel